• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Johnson & Johnson mulls ‘strategic options’ for diabetes business

Johnson & Johnson mulls ‘strategic options’ for diabetes business

January 24, 2017 By Brad Perriello

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) said today that it’s mulling the proverbial “strategic options” for its diabetes business, including the LifeScan, Animas and Calibra Medical brands.

“Strategic options may include the formation of operating partnerships, joint ventures or strategic alliances, a sale of the businesses, or other alternatives either separately or together,” the healthcare conglomerate said in reporting its 4th-quarter and full-year earnings this morning. “All options will be evaluated to determine the best opportunity to drive future growth and maximize shareholder value. There can be no assurance that this process will result in any transaction or other strategic alternative of any kind.”

Diabetes sales were off for both periods, sliding -3.8% to $462 million during Q4 and -7.2% to $1.79 billion for full-year 2016.

New Brunswick, N.J.-based Johnson & Johnson also said it missed the consensus top-line forecasts but still eked out earnings beats for both the quarter and 2016.

Profits were $3.81 billion, or $1.38 per share, on sales of $18.11 billion for the 3 months ended Dec. 31, 2016, representing a bottom-line gain 18.6% on sales growth of 1.7% compared with Q4 2015. Adjusted to exclude 1-time items, earnings per share were $1.58, 2¢ ahead of the Wall Street consensus estimate; analysts there were looking for sales of $18.28 billion.

Full-year profits grew 7.3% to $16.54 billion, or $5.93 per share, on sales growth of 2.6% to $71.89 billion. Adjusted EPS came in at $6.73, again 2¢ ahead of The Street, but J&J missed the consensus sales number of $72.03 billion.

“We are pleased to report that we accelerated our adjusted growth for 2016 over the prior year, and delivered a strong total shareholder return of greater than 15%. The strong adjusted sales and EPS growth was driven by the impressive performance of our pharmaceutical business and continued momentum in our medical device business and share gains while improving profitability in our consumer business,” chairman & CEO Alex Gorsky said in prepared remarks. “Looking forward to 2017, we expect to continue driving sustainable, long-term growth through the new products, science and innovation that our talented colleagues and partners of Johnson & Johnson are advancing to positively impact human health.”

Johnson & Johnson said it expects to report adjusted EPS of $6.93 to $7.08 on sales of $74.1 billion to $74.8 billion this year.

Medical device sales flat

Including the diabetes division’s declines, J&J’s medical device business posted flat sales for both periods. Fourth-quarter medical device sales were up 0.2% to $6.44 billion; full-year sales slipped -0.1% to $25.12 billion. Here’s a look at how the division broke down:

Q4 2016
Cardiovascular $485.00 10.5% $1,849.00 -9.2%
Diabetes $462.00 -3.8% $1,789.00 -7.2%
Ortho $2,387.00 -1.5% $9,334.00 0.8%
Surgery $2,387.00 -1.1% $9,296.00 0.9%
Vision $721.00 11.3% $2,785.00 6.8%

JNJ shares were off -2.5% to $111.11 each today in pre-market trading.

Filed Under: MassDevice Earnings Roundup, Mergers & Acquisitions, Wall Street Beat Tagged With: Johnson and Johnson

More recent news

  • Johnson & Johnson MedTech launches new Volt plating systems for radius, humerus
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor
  • Anaconda Biomed wins CE mark for funnel catheter
  • FDA approves Neuspera neuromod for urinary incontinence

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy